Tarsus Pharmaceuticals Inc

{ "date": [ "202612", "202712", "202812", "202912", "203012" ], "revenue_estimate": [ 697.6, 906.47, 1092.63, 1263.29, 1455.24 ], "ebit_estimate": [ -27.43, 163.02, 332.07, 482.73, 687.3 ], "ebitda_estimate": [ -31.31, 180.08, 259, 159, null ], "net_income_estimate": [ -29.39, 157.96, 307.61, 435.65, 612.75 ], "per_share_eps_estimate": [ -0.71, 3.21, 5.62, 8.32, 11.59 ], "eps_nri_estimate": [ -0.7, 3.16, 5.4, 7.64, 10.58 ], "dividend_estimate": [ null, null, null, null, null ], "book_value_per_share_estimate": [ null, null, null, null, null ], "pretax_income_estimate": [ -41.42, 168.72, 328.72, 499.45, 711.03 ], "operating_cash_flow_per_share_estimate": [ -1.11, 3.58, null, null, null ], "roa_estimate": [ 3.9, 12.9, null, null, null ], "roe_estimate": [ -8.02, 22.8, null, null, null ], "gross_margin_estimate": [ 93.05, 93.05, 93, 93, 93 ], "operating_cash_flow_estimate": [ -47.68, 153.79, null, null, null ], "pettm_estimate": [ 0, 18.09, 10.35, 6.99, 5.02 ], "long_term_growth_rate_mean": 0, "long_term_revenue_growth_rate_mean": "33.83", "future_per_share_eps_estimate_growth": null, "future_eps_nri_estimate_growth": null, "future_revenue_estimate_growth": 33.83, "future_ebit_estimate_growth": null, "future_ebitda_estimate_growth": null, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": null, "future_pretax_income_estimate_growth": null, "future_book_value_per_share_estimate_growth": null, "future_roa_estimate_growth": null, "future_roe_estimate_growth": null, "future_gross_margin_estimate_growth": -0.06, "future_operating_cash_flow_per_share_estimate_growth": null }

{ "date": [ "202606", "202609", "202612", "202703", "202706", "202709", "202712", "202803" ], "revenue_estimate": [ 167.83, 175.96, 194.04, 190.77, 215.75, 224.47, 244.17, 250.37 ], "ebit_estimate": [ -11.16, -7.68, 0.66, -2.9, 26.3, 40.6, 61.6, null ], "ebitda_estimate": [ -2.45, 2.59, -4.96, null, null, null, null, null ], "net_income_estimate": [ -10.63, -7.04, -0.86, -1.4, 27.9, 42.2, 63.1, null ], "per_share_eps_estimate": [ -0.23, -0.15, -0.05, null, 0.39, 0.56, 0.7, 0.73 ], "eps_nri_estimate": [ -0.25, -0.17, -0.04, -0.02, 0.5, 0.73, 1.02, 0.73 ], "dividend_estimate": [ null, null, null, null, null, null, null, null ], "book_value_per_share_estimate": [ null, null, null, null, null, null, null, null ], "pretax_income_estimate": [ -11.37, -18.9, -0.18, -1.4, 27.9, 42.2, 63.1, null ], "operating_cash_flow_per_share_estimate": [ null, null, null, null, null, null, null, null ], "roa_estimate": [ null, null, null, null, null, null, null, null ], "roe_estimate": [ null, null, null, null, null, null, null, null ], "gross_margin_estimate": [ 93.15, 93, 92.9, null, null, null, null, null ], "operating_cash_flow_estimate": [ null, null, null, null, null, null, null, null ], "pettm_estimate": [ 0, 76.99, 36.33, null, 24.42, null, null, null ], "long_term_growth_rate_mean": 0, "long_term_revenue_growth_rate_mean": "33.83", "future_per_share_eps_estimate_growth": null, "future_eps_nri_estimate_growth": null, "future_revenue_estimate_growth": 33.83, "future_ebit_estimate_growth": null, "future_ebitda_estimate_growth": null, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": null, "future_pretax_income_estimate_growth": null, "future_book_value_per_share_estimate_growth": null, "future_roa_estimate_growth": null, "future_roe_estimate_growth": null, "future_gross_margin_estimate_growth": -0.06, "future_operating_cash_flow_per_share_estimate_growth": null }